Preterm Labor Treatment Market report gives a comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report on global market gives historical, current, and future market sizes (US$ Mn) of drugs (tocolytic drugs (beta – mimetic, calcium channel blockers, nsaids), corticosteroids, magnesium sulphate, antibiotics, others)), dosage form (tablets, capsules, injections), end user (hospitals, pediatric and neonatal clinics, nursing homes, pharmacy) and geographic regions. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of preterm labor treatment market In April 2016, AMAG Pharmaceuticals introduced FDA approved single dose, preservative free Makena to reduce risk of preterm birth. The flare-up of the Covid-19 pandemic and high danger of preterm birth related with Covid-19 disease has upsurged the interest for its testing arrangements. As indicated by the information distributed by CDC, pregnant women with Covid-19 are at increased danger for basic entanglements and may be at high danger for preterm birth.